混合心脏磁共振/氟脱氧葡萄糖正电子发射断层成像鉴别活动性与慢性心脏结节病
本研究前瞻性纳入43例活检证实的胸外结节病患者,采用3-T混合PET/MR扫描评估疑似心脏结节病。以PET与CMR(LGE或T1/T2 mapping)均阳性定义为活动性CS,PET阴性但CMR阳性为慢性CS。结果显示混合CMR/FDG-PET有助于检出CS并鉴别活动性疾病,T1 mapping在LGE阴性患者中可额外发现CS。
要点
- 混合CMR/FDG-PET可同时评估心肌FDG摄取与CMR结构/组织特征,帮助区分活动性与慢性CS。
- T1 mapping在LGE阴性患者中可额外发现22%的CS,提示LGE阴性不能排除CS。
- PET与CMR(LGE或T1/T2 mapping)均阳性定义为活动性CS,PET阴性但CMR阳性为慢性CS。
关键影像表现/征象
- 43例中36例(84%)成功抑制心肌葡萄糖摄取。
- 混合CMR/FDG-PET显示活动性CS 13例(36%),慢性CS 5例(14%),无CS 18例(50%)。
- LGE阳性14例(39%),T1 mapping异常10例(27%),T2 mapping异常2例(6%)。
- 18例CS患者中4例(22%)LGE阴性但T1 mapping异常而诊断CS。
- PET FDG摄取阳性17例(47%)。
诊断标准与关键数值
- 活动性CS定义为PET和CMR(LGE或T1/T2 mapping)均阳性(PET+/CMR+)。
- 慢性CS定义为PET阴性但CMR阳性(PET-/CMR+)。
- 无CS定义为无论PET结果如何,CMR阴性。
临床应用与阅片要点
- 阅片时应综合评估PET心肌FDG摄取与CMR的LGE及T1/T2 mapping,避免仅凭LGE阴性排除CS。
- 报告时应注明心肌葡萄糖摄取抑制是否成功,因其影响FDG-PET判读。
- 对LGE阴性但T1 mapping异常的患者,应提示可能为CS,尤其临床怀疑时。
- 区分活动性与慢性CS需结合PET代谢活性与CMR组织特征,活动性CS可能提示抗炎治疗获益。
局限性
- 样本量较小(43例),单中心前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of this study was to investigate the diagnostic value of simultaneous hybrid cardiac magnetic resonance (CMR) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection and differentiation of active (aCS) from chronic (cCS) cardiac sarcoidosis.
BACKGROUND: Late gadolinium enhancement (LGE) CMR and FDG-PET are both established imaging techniques for the detection of CS. However, there are limited data regarding the value of a comprehensive simultaneous hybrid CMR/FDG-PET imaging approach that includes CMR mapping techniques.
METHODS: Forty-three patients with biopsy-proven extracardiac sarcoidosis (median age: 48 years, interquartile range: 37-57 years, 65% male) were prospectively enrolled for evaluation of suspected CS. After dietary preparation for suppression of myocardial glucose metabolism, patients were evaluated on a 3-T hybrid PET/MR scanner. The CMR protocol included T1 and T2 mapping, myocardial function, and LGE imaging. We assumed aCS if PET and CMR (ie, LGE or T1/T2 mapping) were both positive (PET+/CMR+), cCS if PET was negative but CMR was positive (PET-/CMR+), and no CS if patients were CMR negative regardless of PET findings.
RESULTS: Among the 43 patients, myocardial glucose uptake was suppressed successfully in 36 (84%). Hybrid CMR/FDG-PET revealed aCS in 13 patients (36%), cCS in 5 (14%), and no CS in 18 (50%). LGE was present in 14 patients (39%); T1 mapping was abnormal in 10 (27%) and T2 mapping abnormal in 2 (6%). CS was diagnosed based on abnormal T1 mapping in 4 out of 18 CS patients (22%) who were LGE negative. PET FDG uptake was present in 17 (47%) patients.
CONCLUSIONS: Comprehensive simultaneous hybrid CMR/FDG-PET imaging is useful for the detection of CS and provides additional value for identifying active disease. Our results may have implications for enhanced diagnosis as well as improved identification of patients with aCS in whom anti-inflammatory therapy may be most beneficial.
引用
- Greulich S, Gatidis S, Gräni C, et al. Hybrid Cardiac Magnetic Resonance/Fluorodeoxyglucose Positron Emission Tomography to Differentiate Active From Chronic Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2021. PMID: 34656480. doi:10.1016/j.jcmg.2021.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。